Key Details
Price
$510.00Last Dividend
$0.39Annual ROE
13.18%Beta
0.60Events Calendar
Next earnings date:
Jan 31, 2025Recent quarterly earnings:
Oct 23, 2024Recent annual earnings:
Jan 31, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Dec 13, 2024Next split:
N/ARecent split:
June 06, 1996Analyst ratings
Recent major analysts updates
Screeners with TMO included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
LAKEWOOD, N.J.--(BUSINESS WIRE)--Knipper Health, Inc., the leading provider of comprehensive pharmaceutical marketing services in the U.S. for the biopharmaceutical and medical sectors, has announced that it will take over the sample and fulfillment services of Patheon Pharma Services from Thermo Fisher Scientific in Memphis, TN. As part of this transition, Knipper will keep all employees and the Memphis location, along with all existing customers.
TMO's recent strategic purchases, such as the $3.1 billion acquisition of Olink Holdings, are expected to boost their growth in the future.
Thermo Fisher's stock is currently considered a "buy" because there are signs of recovery, such as positive sales growth and stable profit margins, even though there have been some recent downturns. The company is overcoming its post-pandemic difficulties, with encouraging remarks from executives and better forecasts for 2024, suggesting a possible return to organic growth. Additionally, potential deregulation under Trump's administration might boost demand for Thermo Fisher's products in a more competitive pharmaceutical industry.
Investors are worried about Thermo Fisher's ongoing drop in testing revenues because there is less demand for COVID testing.
Investors remain hopeful about Thermo Fisher because of its smart acquisitions and a series of new product releases.
Thermo Fisher Scientific is in a good position to grow because it has steady income, a strong history of mergers and acquisitions, and is not heavily affected by the economy. Although the company saw a rise in revenue during COVID-19 followed by a decline, its current valuation seems fair, suggesting there is room for growth in value. Factors that could drive growth in 2025 include better funding for biotech and government support in China.
Thermo Fisher has introduced CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8 to improve the development and production of cell therapies.
One of TMO's recent important purchases that could boost its growth in the future is the $3.1 billion acquisition of Olink Holdings.
Thermo Fisher Scientific Inc. (NYSE:TMO) will hold the Wolfe 2024 Healthcare Results Conference on November 19, 2024, at 8:00 AM ET. The company will be represented by Marc Casper, who is the Chairman, President, and CEO. Doug Schenkel from Wolfe Research will also be participating in the conference call.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in scientific services, has announced that its Board of Directors has approved a plan to buy back $4 billion worth of its common stock either in the open market or through negotiated deals. This new authorization does not have an expiration date and replaces the previous plan, which had $1 billion left. About Thermo Fisher Scientific: Thermo Fisher Scientific Inc. is a leading company in its field.
FAQ
- What is the primary business of Thermo Fisher Scientific?
- What is the ticker symbol for Thermo Fisher Scientific?
- Does Thermo Fisher Scientific pay dividends?
- What sector is Thermo Fisher Scientific in?
- What industry is Thermo Fisher Scientific in?
- What country is Thermo Fisher Scientific based in?
- When did Thermo Fisher Scientific go public?
- Is Thermo Fisher Scientific in the S&P 500?
- Is Thermo Fisher Scientific in the NASDAQ 100?
- Is Thermo Fisher Scientific in the Dow Jones?
- When was Thermo Fisher Scientific's last earnings report?
- When does Thermo Fisher Scientific report earnings?
- Should I buy Thermo Fisher Scientific stock now?